Stay updated on Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating an update in the clinical efficacy evaluation of MK-3475 (pembrolizumab) as the first systemic intervention for patients with advanced Merkel cell carcinoma (MCC) in a phase II trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:38.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for patients, specifying that researchers are looking for individuals with biopsy-proven metastatic or recurrent locoregional Merkel Cell Carcinoma (MCC) following standard therapy. Previously, no specific information was provided in this section.
    Difference
    59%
    Check dated 2024-05-22T21:02:45.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:02:09.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Advanced Merkel Cell Cancer Clinical Trial page.